The relationship between PSAD, Gleason score, sF and bone metastasis in patients with prostate cancer

Abstract

Objective To investigate the diagnostic value of prostate specific antigen density (PSAD), Gleason score and serum ferritin (SF) in bone metastases from prostate cancer. Methods 45 patients diagnosed with bone metastases from prostate cancer in our hospital from January 2015 to October 2017 were selected as metastasis group. 90 cases without bone metastases in prostate cancer were selected as control group. The PSAD, SF and Gleason scores of the two groups were measured and compared. Receiver operating characteristic (ROC) curve was used to analyze the three indexes to predict the clinical value of bone metastases in patients with prostate cancer. Results The serum PSA, SF, prostate volume, PSAD levels in metastasis group were significantly higher than those in the control group, with statistically significant difference (P<0.05); the average Gleason scores metastasis group were significantly higher than the control group (P<0.05); The sensitivity and specificity of SF combined with PSAD and Gleason score diagnosis in patients with prostate cancer bone metastasis was 95.64% and 91.30% respectively, the area under the curve (AUC) value is 0.930. Conclusions Detection and analysis of PSAD, SF, and Gleason scores in patients with prostate cancer will help to evaluate whether or not the patients have bone metastases. Key words: Prostatic neoplasms/PA; Bone neoplasms/SE; Prostate-specific antigen/ME; Ferritins/ME; Neoplasm grading